BioCryst Pharmaceuticals Inc (NAS:BCRX)
$ 7.82 -0.37 (-4.52%) Market Cap: 1.62 Bil Enterprise Value: 2.18 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 75/100

Q1 2023 BioCryst Pharmaceuticals Inc Earnings Call Transcript

May 03, 2023 / 12:30PM GMT
Release Date Price: $8.29 (+12.48%)
Operator

Good morning, and welcome to the BioCryst Q1 2023 Earnings Conference Call. (Operator Instructions) Please note this event is being recorded.

I would now like to turn the conference over to John Bluth at BioCryst. Please go ahead.

John D. Bluth
BioCryst Pharmaceuticals, Inc. - Chief Communications Officer

Thank you very much. Good morning, and welcome to BioCryst's First Quarter 2023 Corporate Update and Financial Results Conference Call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer; and Chief R&D Officer, Dr. Helen Thackray. Following our remarks, we'll answer your questions.

Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot